The occurrence of a venous thromboembolic event (VTE) among cancer patients has been rising steadily by up to threefold in some series with respect to the general population [1–3]. This risk is especially important for individuals undergoing chemotherapy or targeted therapy. During the course of their disease, 4–20 % of all oncology patients will experience a VTE, largely depending on tumor type and stage [4,5]. In recent years, the molecular landscape of the tumor has been proposed as an additional factor to account when assessing the risk of thrombosis.
